Saturday, October 31, 2026
ExploreSearch
Finance Via News

AI Market & Investment

2 articles

Generative AI Production Costs Drop 99% as Enterprise Players Target $500M Revenue by 2026

Generative AI Production Costs Drop 99% as Enterprise Players Target $500M Revenue by 2026

Per-minute AI generation costs fell from hundreds of dollars to single digits, enabling enterprise deployment across marketing, drug discovery, and manufacturing. Rezolve AI projects $500M annual recurring revenue by 2026 as teams of 10 now handle work previously requiring 50-100 people. Copyright issues and training data licensing remain barriers to adoption.

ViaNews Editorial Team (Finance)•
Regional LLM Markets Face Governance Headwinds as AI Safety Scrutiny Intensifies

Regional LLM Markets Face Governance Headwinds as AI Safety Scrutiny Intensifies

Large language model expansion into regional markets is colliding with heightened regulatory scrutiny as safety concerns mount. Google's medical AI advice now carries buried warnings, while antimicrobial-resistant infections kill 4 million annually—a figure driving investor attention to AI-powered diagnostics. The convergence of governance pressure and market growth is reshaping corporate deployment timelines.

ViaNews Editorial Team (Finance)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com